Oria, Victor O.
Zhang, Hongyi
Zito, Christopher R.
Rane, Chetan K.
Ma, Xian-Yong
Provance, Olivia K.
Tran, Thuy T.
Adeniran, Adebowale
Kluger, Yuval
Sznol, Mario
Bosenberg, Marcus W.
Kluger, Harriet M.
Jilaveanu, Lucia B. http://orcid.org/0000-0001-8900-5083
Funding for this research was provided by:
National Cancer Institute (R01CA204002, R01 CA216846, K12CA215110)
Melanoma Research Alliance (#308721)
American Cancer Society (130157-RSG-16-216-01-TBG)
National Institutes of Health (KL2 TR000140)
Article History
Received: 9 January 2022
Revised: 19 April 2022
Accepted: 8 May 2022
First Online: 23 June 2022
Declarations
:
: HMK reports grants (outside of the submitted work) from Merck, Bristol-Myers Squibb and Apexigen and personal fees from Nektar, Iovance, Celldex, Array Biopharma, Merck, Elevate Bio, Instil Bio, Bristol-Myers Squibb, Clinigen, Shionogi, Chemocentryx, Calithera, and Signatero. MS reports stock or stock options at: Adaptive Biotechnologies—stock options, Amphivena—stock options, Intensity—stock options, Actym—stock options, Johnson and Johnson—stock, Glaxo-Smith Kline—stock, Evolveimmune—stock options, Nextcure—stock options, Repertoire—stock options, Oncohost—stock options. MS also reports consulting fees from Kanaph, Adagene, Asher, Targovax, Ontario Institute for Cancer Research, Gilead, Sapience, iTEOS, Incyte, Pfizer, Jazz Pharmaceuticals, Tessa, Oncosec, Biontech, Trillium, Stcube, Regeneron, Simcha, Numab, Incyte, Astra Zeneca, Molecular Partners, Idera, Apexigen, Evolveimmune, Alligator, Verastem, Agenus, Rubius, Bristol-Myers, Genentech-Roche, Boston Pharmaceuticals, Nextcure, Servier, Adaptimmune, Immunocore, Dragonfly, Pierre-Fabre, Boehringer Ingelheim, Innate pharma, Nektar, Pieris, Abbvie, Zelluna, Seattle Genetics, Genocea, GI Innovation, Chugai-Roche, Lilly, Modulate Therapeutics, Genmab, and Biond. All the remaining authors have no potential conflicts of interest to disclose.
: All authors consent to the publication of this study.